Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,007 Mln
Revenue (TTM)
$272 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
23.7
Industry P/E
--
EV/EBITDA
33.4
Div. Yield
0 %
Debt to Equity
4.8
Book Value
$1.4
EPS
$-0.1
Face value
--
Shares outstanding
37,037,453
CFO
$-27.05 Mln
EBITDA
$-33.68 Mln
Net Profit
$-104.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
| -27.7 | -34.6 | -27.7 | 33.2 | 18.7 | 39.3 | 24.5 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
| 46.1 | 196.9 | -24.1 | 70.8 | 25.9 | -11.8 | 36.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
|
35.4 | 2,006.7 | 272.3 | -5.1 | 3.7 | -8.4 | -- | 23.7 |
| 9.1 | 2,179.2 | 510.2 | 146.9 | 37.2 | 35.6 | 15.5 | 4.6 | |
| 12.7 | 3,812.0 | 3,018.8 | 72.1 | 12.6 | -80 | 54.3 | 86.1 | |
| 171.8 | 8,210.1 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.9 | |
| 74.5 | 13,446.3 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 42.0 | 4,055.0 | 761.4 | 99.7 | 7.3 | 15 | 46.5 | 5.7 | |
| 13.5 | 11,237.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 18.7 | 2.9 | |
| 23.1 | 11,653.6 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.3 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 199.6 | 3,841.5 | 268.1 | 124.5 | 60.0 | 13.5 | 31.5 | 4.0 |
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers... ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Address: 1A Burton Hills Boulevard, Nashville, TN, United States, 37215 Read more
CEO & Chairman of the Board
Mr. Mark L. Baum J.D.
CEO & Chairman of the Board
Mr. Mark L. Baum J.D.
Headquarters
Nashville, TN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Harrow Health Inc (HROW) is $35.43 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Harrow Health Inc (HROW) has given a return of 18.75% in the last 3 years.
Since, TTM earnings of Harrow Health Inc (HROW) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-350.51
|
34.35
|
|
2024
|
-68.72
|
17.25
|
|
2023
|
-16.22
|
5.63
|
|
2022
|
-30.83
|
16.16
|
|
2021
|
-13.18
|
21.03
|
The 52-week high and low of Harrow Health Inc (HROW) are Rs 54.85 and Rs 20.85 as of 02-Apr-2026.
Harrow Health Inc (HROW) has a market capitalisation of $ 2,007 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Harrow Health Inc (HROW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.17
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.